GE Healthcare Technologies Inc

Análisis de la acción GE Healthcare Technologies Inc (GEHC)

$69.760

+0.188 (+0.27%)Al cierre

Loading chart…
Máximo
70.080
Apertura
69.290
Precio medio ponderado por volumen
69.63
Volumen
2.28M
Capitalización
35.98B
Mínimo
69.060
Importe
158.66M
EV/EBITDA, TTM
9.85

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

Análisis de IA of GE Healthcare Technologies Inc (GEHC)

Comprar

GE Healthcare Technologies Inc is a good buy right now, trading at $69.57 with a forward P/E of 12.12, indicating it is undervalued compared to its growth potential. The recent acquisition of SOFIE Biosciences for $945 million is expected to enhance revenue growth and market competitiveness, which is a strong positive catalyst. However, the stock has a 1-year change of -7.83%, indicating some volatility and risk.

Métricas de valoración

El PER previsto actual de GE Healthcare Technologies Inc (GEHC) es 12.12, frente a su media de 5 años de 17.47.

PER previsto

Muy infravalorado
Media 5A P/E
17.47
P/E actual
12.12
Sobrevalorada
19.91
Infravalorada
15.03

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
11.33
EV/EBITDA actual
9.85
Sobrevalorada
12.84
Infravalorada
9.83

Precio/ventas previsto

Infravalorado
Media 5A P/S
1.67
P/S actual
1.39
Sobrevalorada
1.95
Infravalorada
1.40

Escenarios de precio de Alphio AI para GEHC

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%GEHC

$83.18

Precio del escenario

B

Base

Base · 50%GEHC

$81.20

Precio del escenario

B

Bajista

Bajista · 25%GEHC

$74.35

Precio del escenario

Ballenas con GEHC en cartera

H

Hotchkis and Wiley Capital Management, LLC

+ Con en carteraGEHC

+7.59%

Rentabilidad a 3 meses

B

Barrow, Hanley, Mewhinney & Strauss, LLC

+ Con en carteraGEHC

+4.67%

Rentabilidad a 3 meses

I

ICICI Prudential Asset Management Company Limited

+ Con en carteraGEHC

+2.52%

Rentabilidad a 3 meses

L

Locust Wood Capital Advisers, LLC

+ Con en carteraGEHC

+1.40%

Rentabilidad a 3 meses

H

Homestead Advisers Corp.

+ Con en carteraGEHC

+1.06%

Rentabilidad a 3 meses

G

Grandfield & Dodd, LLC

+ Con en carteraGEHC

+0.78%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-19 (ET)

09:30:00

GE HealthCare Launches New LOGIQ Focus Ultrasound System

2026-10-16 (ET)

09:30:00

GE HealthCare Publishes Anesthesia Study from University of Michigan

2026-10-15 (ET)

08:30:00

GE HealthCare Announces MINItrace Magni Achieves CE Mark

2026-10-05 (ET)

16:30:00

Nasdaq Rises Nearly 300 Points as Market Digests Jobs Report

12:30:00

Nasdaq Rises Nearly 200 Points, Led by Tech Stocks

Noticias

Preguntas frecuentes sobre GEHC, respondidas por Alphio AI

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

GE Healthcare Technologies Inc is a good buy right now, trading at $69.57 with a forward P/E of 12.12, indicating it is undervalued compared to its growth potential. The recent acquisition of SOFIE Biosciences for $945 million is expected to enhance revenue growth and market competitiveness, which is a strong positive catalyst. However, the stock has a 1-year change of -7.83%, indicating some volatility and risk.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar